PubMed Health⌕ Search

Biomedical subjects

F Buitrago

Publications and source records attributed to F Buitrago.

At least 19 recordsLinked to original sources

[Evaluation of the efficacy of a comprehensive programme of secondary prevention of cardiovascular disease in primary care: the PREseAP Study].

OBJECTIVES: To assess the efficacy of a comprehensive secondary prevention programme to reduce morbidity and mortality in patients who have suffered a cardiovascular (CV) event; to control CV risk factors and prophylactic treatment in order to prevent recurrence; and to improve the quality of life of patients with cardiovascular disease. DESIGN: Randomised, pragmatic, open clinical trial in primary care. SETTING: A total of 42 primary care centres of 8 different areas in Spain. PARTICIPANTS: Men and women below 86 years old, diagnosed with coronary disease and/or stroke and/or peripheral vascular disease in the preceding year, and who have no serious or terminal disease. INTERVENTION: Primary care centres will be randomised to following usual care (control group), or to following a comprehensive programme of secondary prevention (intervention group). MAIN MEASUREMENTS: Cardiovascular fatal events, cardiovascular non-fatal events, total mortality and health-related quality of life (SF-36).

Adult↗

[Drug savings and the outpatient monitoring of arterial pressure in a group of hypertensive patients].

OBJECTIVE: To evaluate whether the introduction of out-patient blood pressure monitoring (OBPM) to follow up patients diagnosed with light hypertension (HT) decreases the use of medicines and so saves money. DESIGN: An observational study. SETTING: Urban health centre. PATIENTS AND OTHER PARTICIPANTS: Patients with light HT not being treated with medication, with two or less cardiovascular risk factors and who had type 0 or 1 curves in OBPM and a mean daily blood pressure < 135/85 mm Hg. MEASUREMENTS AND MAIN RESULTS: OBPM over 24 hours with a Spacelabs 90202 oscillometer. 23 patients (15 women), average age 38.6 +/- 8, were studied. Savings generated ranged from 153,628 pesetas, when the cheapest thiazide diuretic was prescribed, to 5,208,258 pesetas, when the dearest ACEI was chosen. CONCLUSIONS: Monitoring HT with OBPM led to a decrease in the use of medicines to combat hypertension, with considerable savings. These findings cannot be generalised. We believe that Primary Care must have access to OBPM in order to manage hypertension, apart from the savings involved.

Adult↗

Identification of rat liver glucose-3-phosphatase as an inositol monophosphatase inhibited by lithium.

Glucose-3-phosphatase (Glc3Pase) from rat liver has been purified 780-fold with a 4% recovery. The substrate specificity of the purified enzyme agreed with that of inositol monophosphatase (EC 3.1.3.25). D-Glucose 3-phosphate (D-Glc(3)P; K(m) = 200 microM) was hydrolyzed with an efficiency similar to DL-myo-inositol 1-monophosphate (DL-Ins(1)P; K(m) = 80 microM), since the ratio V(max)/K(m) was similar for both substrates. Purification data, coelution of activities, thermal inactivation curves, optimal pH, bivalent cation requirements, inhibition by Li+, molecular weight, and isoelectric pH comparisons supported that the hydrolysis of D-Glc(3)P and DL-Ins(1)P was catalyzed by a unique phosphohydrolase identified as a hepatic form of the lithium-sensitive inositol monophosphatase. That the hydrolysis of D-Glc(3)P is a genuine feature of inositol monophosphatases was confirmed because the enzyme purified from bovine brain showed also Glc3Pase activity, and inspection of published 3D models of inositol monophosphatase complexes with D(L)-Ins(1)P or D(L)-Ins(4)P indicated that beta(alpha)-D-Glc(3)P in a pyranose conformation with all (but one) the hydroxy groups in equatorial orientation would fit in the active site as other good substrates do. The results of this work are suggestive of possible relationships between inositol and sugar 3-phosphate metabolism.

Animals↗

[Reliability of 3 sources of information about medication excipients].

OBJECTIVE: To find how reliably three sources of therapeutic information record the composition of excipients: the Vademecum, the pharmaceutical catalogue and the instructions sheets of pharmaceutical products. DESIGN: Descriptive study. SETTING: Primary care. PATIENTS AND OTHER PARTICIPANTS: Initially, 658 orally-taken products were selected. Whether four excipients (saccharine, saccharose, lactose and ethanol) appeared in these products' composition formulas was compared. RESULTS: In 70.6% +/- 5.11 there was discordance on the excipients in the composition formulas in one of the three sources of therapeutic information. The instructions sheets contained information on the number of excipients in 98.7% +/- 1.3 of the products, the pharmaceutical catalogue in 87.2% +/- 3.7 and the Vademecum in 65.7% +/- 5.3. So the Vademecum was the source of therapeutic information containing the highest percentage of products with no kind of information about excipients, followed by the catalogue and the instructions sheets. The instructions sheets were the best source of therapeutic information for 289 products. 10.3% of laboratories did not quantify their excipients in any of the three sources under study. CONCLUSIONS: The Vademecum and pharmaceutical catalogue do not include very reliable information about these four excipients in the composition formulas of pharmaceutical products. It is important to make available to doctors straightforward texts which provide more reliable and up-to-date information.

Drug Information Services↗